|
Reclazepam
|
|
| Systematic (IUPAC) name | |
| 2-[7-chloro-5-(2-chlorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-1-yl]-1,3-oxazol-4(5H)-one | |
| Identifiers | |
| CAS number | |
| ATC code | none |
| PubChem | |
| Chemical data | |
| Formula | C18H13Cl2N3O2 |
| Mol. mass | 374.221 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Reclazepam is a drug which is a benzodiazepine derivative. It has sedative and anxiolytic effects similar to those produced by other benzodiazepine derivatives, and has a short duration of action.[1]
See also
References
- ^ Pscyhotropics.dk (20 January 1986). "reclazepam". http://www.psychotropics.dk/moleculeView/default.aspx?ID=1442&Catalogtype=A&ChapterID=1&Thissortorder=39. Retrieved 24 August 2009.
| This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)




